PET-CT for Kidney Cancer: — Why FDG Is Unreliable

Not necessarily. NCCN and ESMO guidance supports contrast CT as the standard staging scan for kidney cancer, not FDG PET. The two reasons FDG fails — low tumour glucose uptake and urinary interference — mean that PET often adds little for the kidney itself. If you are concerned something has been missed, ask your oncologist what the contrast CT showed and whether there are any sites that would benefit from additional imaging. That is a better question than requesting a scan by name.

Possibly, but not reliably for all bone metastases. FDG PET can pick up some bone deposits, though kidney cancer bone metastases are often less FDG-avid than those from other cancers. If bone spread is suspected — because of pain, a raised blood calcium, or a CT finding — your team may use a dedicated bone scan or MRI of specific areas alongside or instead of PET. Ask your oncologist which approach fits your situation.

Research into alternative tracers for kidney cancer is ongoing, but no single tracer has been adopted as a clinical standard for renal cancer in the way PSMA-PET has been for prostate cancer. For most patients in standard care, contrast CT and MRI remain the recommended imaging tools. If your team mentions a specific tracer in the context of a clinical trial or specialist referral, ask what additional information it is expected to provide and what it would change about your management.

The brightness in the kidney area on a PET scan is almost certainly FDG in your urine, not tumour activity. Your kidneys filter the tracer continuously during the scan, and FDG accumulates in the collecting system of the kidney, the ureter and the bladder. This is normal and expected. Radiologists reading kidney scans account for it, but it is one of the main reasons the scan cannot be read the same way as a scan of the chest or lymph nodes.

Some people with kidney cancer do have PET scans ordered during or after treatment — typically to assess sites away from the kidney, to investigate a finding on CT, or to evaluate response in metastatic disease. Whether you need one depends on your individual situation. It is not something to arrange independently, because the result needs to be interpreted alongside your CT findings and treatment history to be meaningful.

At CION, PET-CT scans are coordinated with partner imaging centres rather than performed on-site. Your oncologist or clinical team will make the referral and ensure the images and report return to your treating team. You do not need to organise this yourself. If you have questions about timing or where the scan will take place, the team at your CION centre can advise you before the appointment is confirmed.